Compass Therapeutics Inc
Company Profile
Business description
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
Contact
80 Guest Street
Suite 601
BostonMA02135
USAT: +1 617 500-8099
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
35
Stocks News & Analysis
stocks
Perplexing buyback from overvalued ASX share
stocks
Most popular shares in SMSFs
stocks
Will China strong arm BHP into lower iron ore prices?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,183.30 | 72.50 | -0.78% |
| CAC 40 | 7,918.68 | 0.68 | 0.01% |
| DAX 40 | 24,346.72 | 105.26 | 0.43% |
| Dow JONES (US) | 45,936.32 | 456.72 | 1.00% |
| FTSE 100 | 9,434.87 | 74.53 | -0.78% |
| HKSE | 25,889.48 | 863.11 | -3.23% |
| NASDAQ | 22,650.81 | 446.38 | 2.01% |
| Nikkei 225 | 48,088.80 | 491.64 | -1.01% |
| NZX 50 Index | 13,351.92 | 218.94 | -1.61% |
| S&P 500 | 6,644.98 | 92.47 | 1.41% |
| S&P/ASX 200 | 8,882.80 | 66.30 | -0.74% |
| SSE Composite Index | 3,889.50 | 7.53 | -0.19% |